MEGGLE presents new co-processed excipient and low nitrite grades at CPHI 2025 Frankfurt

Wasserburg, Germany: – MEGGLE will again participate in the Excipients Zone at CPHI Worldwide 2025 in Frankfurt, Europe’s leading exhibition for pharmaceutical ingredients. The company’s exhibit will emphasize technical innovation and product quality in lactose-based excipients.

MEGGLE is one of CPHI’s longest established exhibitors, with an association stretching back over three decades, almost to the founding CPHI Worldwide expo in 1991.

NextGen MicroceLac^® Plus

Centerpieces, displayed on the MEGGLE stand at Booth 8.0P59 in Hall 8 of the Messe Frankfurt, will highlight latest additions to the company’s industry leading portfolio of closely tailored lactose-based excipients for the whole range of pharma applications from direct compression tableting to dry powder inhalation.

One of the new arrivals is the next generation tableting excipient MicroceLac^® Plus, which was optimized for direct compression (DC) and continuous direct compression (CDC) manufacturing, especially when working with challenging APIs, high-dose formulations or mini tablets (minitabs) as oral solid dosage forms. The co-processed blend of alpha-lactose monohydrate and 65 % microcrystalline cellulose (MCC) delivers superior tabletability and ensures tablet hardness, which exceeds the properties of the individual components in the physical mixture.

Low nitrite lactose excipients

MEGGLE will additionally use CPHI 2025 as a showcase for its new premium low-nitrite lactose excipients for nitrosamine risk mitigation management to address pharma industry concerns over nitrosamine impurities.

These new Low Nitrite grades of GranuLac® 200 and 230, Tablettose® 100, and FlowLac® 100 have nitrite values below 0.10 ppm. Nitrite testing is no pharmacopoeial requirement. Nevertheless, MEGGLE has developed a superior measurement method using ion chromatography to accurately detect nitrite levels down to a quantification limit (LOQ) of 0.03 ppm. Through additional  validation, MEGGLE has demonstrated to be able to safely specify a limit of ≤ 0.10 ppm, as stipulated as a target in the USP Nitrosamine Exchange Forum. MEGGLE measures the nitrite content in each lot of the low nitrite grades and includes the measured nitrite value in the Certificate of Analysis (CoA).

Meeting industry needs

MEGGLE  will also highlight its highly sophisticated spray drying and other contract manufacturing offers that take advantage of Wasserburg’s advanced facilities. Stand design is also focused on hospitality, providing comfortable places to meet MEGGLE experts in Sales, Application Technology and R&D.

The MEGGLE exhibition team in Frankfurt will be again headed by Director Business Unit Excipients Ruth Leinenbach, who commented: “Once again, CPHI Worldwide provide us with one of our best opportunities of the year to connect with our customers, partners and the area sales managers of our various regions.”

“As a team we are highly focused on receiving customer feedback and addressing industry needs.  MicroceLac Plus and these new Low Nitrite grades show that philosophy in action,” added Ms. Leinenbach.

About MEGGLE

Bavarian-based MEGGLE is one of the world’s foremost experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.

MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based pharma excipient solutions, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose^®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose^® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About CPHI 2025 Frankfurt

Now in its 36th year, CPHI is Europe’s flagship annual trade show for pharmaceutical ingredients and partner sourcing. The event attracts more than 60,000 visitors and nearly 2,500 exhibitors from around the globe.

Since its rebranding in 2022, CPHI has combined one of Europe’s largest physical exhibitions with a year-round online platform for networking and sourcing.

For 2025, CPHI returns to Frankfurt for a three-day event opening October 28 at the Frankfurt Messe. Exhibitor zones will include Machinery & Equipment, Finished Dosage, Packaging & Drug Delivery, APIs, Excipients, Bioproduction, Integrated Pharma, Natural Extracts, and Fine Chemicals. New zones for 2025 will showcase Cleanroom Solutions, Cold Chain & Logistics, and Sustainability suppliers.

CPHI is organized by Informa Markets, with further information at:  https://www.cphi.com/europe/en/home.html

Resources

Click on MEGGLE Low Nitrite Grades to learn more.
Click on MicroceLac Plus for further information.